Feel Comfortable Holding PCSK9 Inhibitors During a Hospital Stay
You'll hear buzz about using the PCSK9 inhibitors, evolocumab (Repatha) or alirocumab (Praluent), in patients with CV disease.
These injectable meds lower LDL cholesterol by about 60%...even in those on a high-intensity statin (atorvastatin 80 mg, etc).
Now evidence suggests that adding evolocumab to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals